Global

Recent News Releases

CSL Behring News Releases

CSL Behring Subscribe to alerts

CSL Limited Financial News


15 November 2016
CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial
AEGIS-1 Phase 2b study meets co-primary endpoints of hepatic and renal safety and demonstrates proof of mechanism - results were presented at AHA 2016. More.

14 November 2016
AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP
Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A. More.

Media Resources

CSL Behring Company Information CSL Behring
Company Information >
CSL Behring Media Contacts CSL Behring
Media Contacts >
CSL Behring Social Media CSL Behring
Social Media >
CSL Behring MultiMedia Library CSL Behring
Images and Videos >



Our Patients' Stories




CSL Behring at a Glance

CSL Behring at a glance







Share
LinkedIn Twitter Facebook Google+